Ground Rents Income Fund Plc News - GRIO

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Hutchmed (China) Limited Sovleplenib NDA Granted Priority Review in China

Hutchmed (China) Limited 11 January 2024 Press Release HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary...

Hutchmed (China) Limited Blocklisting Six Monthly Return

Hutchmed (China) Limited 29 December 2023 Blocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ - Friday, December 29, 2023:...

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited 29 December 2023 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ -- Friday, December 29, 2023: HUTCHMED...

Hutchmed (China) Limited Overseas Regulatory Announcement

Hutchmed (China) Limited 21 December 2023 Overseas Regulatory Announcement - Continuing Connected Transactions HUTCHMED (China) Limited ("...

Hutchmed (China) Limited Inclusion in National Reimbursement Drug List

Hutchmed (China) Limited 13 December 2023 Press Release HUTCHMED Announces Continued Inclusion of ELUNATE(R) (fruquintinib) and SULANDA(R...

Hutchmed (China) Limited Overseas Regulatory Announcement

Hutchmed (China) Limited 07 December 2023 Overseas Regulatory Announcement - Disposal of Interest in Consumer Products Businesses HUTCHMED (China...

Hutchmed (China) Limited Clinical Data to be Presented at Congresses

Hutchmed (China) Limited 01 December 2023 Press Release HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO...

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited 30 November 2023 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ -- Thursday, November 30, 2023: HUTCHMED...

Hutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM) (fruquintinib)

Hutchmed (China) Limited 09 November 2023 HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA(TM) (fruquintinib) for Previously...

Hutchmed (China) Limited Vesting of awards under the LTIP

Hutchmed (China) Limited 24 October 2023 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ...

Hutchmed (China) Limited Clinical Data to be Presented at ESMO 2023

Hutchmed (China) Limited 16 October 2023 Press Release HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023 Hong Kong, Shanghai...

Hutchmed (China) Limited NDA Submission for Fruquintinib in Japan

Hutchmed (China) Limited 29 September 2023 Press Release HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously...

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited 29 September 2023 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ -- Friday, September 29, 2023: HUTCHMED...

Hutchmed (China) Limited Director's Share Dealing

Hutchmed (China) Limited 14 September 2023 Director's Share Dealing Hong Kong, Shanghai & Florham Park, NJ - Thursday, September 14...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Ground Rents Income Fund Plc (GRIO)

Professional-Grade Tools, for Individual Investors.

GRIO News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Hutchmed (China) Limited Sovleplenib NDA Granted Priority Review in China

Hutchmed (China) Limited Blocklisting Six Monthly Return

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited Overseas Regulatory Announcement

Hutchmed (China) Limited Inclusion in National Reimbursement Drug List

Hutchmed (China) Limited Overseas Regulatory Announcement

Hutchmed (China) Limited Clinical Data to be Presented at Congresses

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM) (fruquintinib)

Hutchmed (China) Limited Vesting of awards under the LTIP

Hutchmed (China) Limited Clinical Data to be Presented at ESMO 2023

Hutchmed (China) Limited NDA Submission for Fruquintinib in Japan

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited Director's Share Dealing

GRIO Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Ground Rents Income Fund Plc (GRIO) News

Ground Rents Income Fund Plc (GRIO)

Professional-Grade Tools, for Individual Investors.

GRIO News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Hutchmed (China) Limited Sovleplenib NDA Granted Priority Review in China

Hutchmed (China) Limited Blocklisting Six Monthly Return

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited Overseas Regulatory Announcement

Hutchmed (China) Limited Inclusion in National Reimbursement Drug List

Hutchmed (China) Limited Overseas Regulatory Announcement

Hutchmed (China) Limited Clinical Data to be Presented at Congresses

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM) (fruquintinib)

Hutchmed (China) Limited Vesting of awards under the LTIP

Hutchmed (China) Limited Clinical Data to be Presented at ESMO 2023

Hutchmed (China) Limited NDA Submission for Fruquintinib in Japan

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited Director's Share Dealing

GRIO Discussion

Your Recent History